The Protein That Started FinalDose

They noticed something unusual. When this particular protein finds the genetic sequence it is looking for, it physically changes shape. Normally, that movement is simply part of another biological process. Jeff Liu and his co-founders looked at it and asked a different question: What if that movement could be turned into a switch? And what if that switch could destroy a cancer cell when it detected the right genetic sequence?

That question became FinalDose.

The company is developing a programmable approach designed to identify unwanted cells through specific DNA or RNA sequences. An engineered protein carries a guide that searches for a target sequence inside the cell. If it finds a match, the protein changes shape and activates a molecular switch designed to release a payload that kills the cell. If the target sequence is not there, the switch is not activated.

Importantly, the idea is not to edit the genome. It is to read the information already inside the cell and use that information to decide whether to act. That distinction is also what made the founders realise this could potentially become much more than one cancer drug. Change the genetic sequence being searched for and, in principle, the same underlying system could be redirected toward another target.

Same platform. Different guide. Different disease.

FinalDose filed its foundational patent at the end of April 2026 and says it demonstrated the switch working in the lab six weeks later. But Jeff is equally open about what comes next. Making the switch work is one thing. Getting it safely and effectively to the right cells is another. Delivery remains one of the major problems still to solve.

That combination of enormous ambition and being realistic about the hard parts also shows up in how FinalDose is being built. Every experiment and action has one clear owner. The team accepts the waiting that biology itself requires. Cells need time to grow. But waiting unnecessarily for a decision, booking, reagent or internal process is treated differently.

Perhaps the most interesting principle is that they try to stay attached to the mission, not the asset. If months of work need to be abandoned because a better path has emerged, they move. The goal is not to protect what has already been built. It is to find the shortest path forward.

FinalDose starts with cancer, but Jeff and his co-founders are thinking beyond it. Their bigger question is whether unwanted cells could eventually be identified by the genetic information inside them and selectively removed. That is a very big question.

And it all started with three scientists looking at a protein changing shape and wondering: What else could we make that movement do?

Welcome to Founder Stories, the people, ideas and moments behind the companies on The Million Token Window.

Further reading: The Final Frontier for Ending Cancer, Startup to Follow.